Author details

Full Name

Guillaume B E Stewart-Jones

Affiliation

ORCID

Career Start Year

2002

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37098956	Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.		2023
36265510	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.	Nat Med	2023
37792954	An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge.		2023
37703353	Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2.	Sci Transl Med	2023
37428933	Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles.		2023
36853802	Potently neutralizing human mAbs against the zoonotic pararubulavirus Sosuga virus.	JCI Insight	2023
35289637	Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines.	Science Translational Medicine	2022
36238717	Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains.	bioRxiv	2022
35452622	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.	Cell	2022
35447072	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.	Cell	2022
36263060	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.	bioRxiv	2022
34815117	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.	Vaccine	2021
34019795	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.	Cell	2021
33532780	mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge.	bioRxiv	2021
33730471	Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.	New England Journal of Medicine	2021
33880468	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.		2021
33876699	Protective antibodies against human parainfluenza virus type 3 infection.	mAbs	2021
33823129	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses.	Immunity	2021
33501442	mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.		2021
34449440	Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection.	J Clin Invest	2021
34551978	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.	Proceedings of the National Academy of Sciences of the United States of America	2021
34956199	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine.	Frontiers in Immunology	2021
34549975	Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.	Journal of Virology	2021
34887575	A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.	Nature Medicine	2021
34369597	Clonotypic architecture of a Gag-specific CD8+ T-cell response in chronic human HIV-2 infection.	European Journal of Immunology	2021
32722908	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.	N Engl J Med	2020
33097791	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone.	Sci Rep	2020
32595632	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development.	Frontiers in Immunology	2020
32756549	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.	Nature	2020
32577634	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.	bioRxiv	2020
32676596	A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone.	bioRxiv	2020
30718403	CD4 receptor diversity in chimpanzees protects against SIV infection.	Proc Natl Acad Sci U S A	2019
31206510	Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates.	PLoS Biology	2019
29548671	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.	Immunity	2018
28982260	Immunization with Clinical HIV-1 Env Proteins Induces Broad Antibody Dependent Cellular Cytotoxicity-Mediating Antibodies in a Rabbit Vaccination Model.	AIDS Research and Human Retroviruses	2018
30403372	Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.	Elife	2018
30420505	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.	Proc Natl Acad Sci U S A	2018
29212041	Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains.	Cell Reports	2017
28445724	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation.	Cell Rep	2017
29021918	Protection of calves by a prefusion-stabilized bovine RSV F vaccine.	npj Vaccines	2017
27463224	Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus.	PLoS One	2016
29675462	An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.	Molecular Therapy - Oncolytics	2016
27114034	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G.	Cell	2016
27478931	Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.	Nat Struct Mol Biol	2016
26098893	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus.	PLoS One	2015
25740988	Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env.	Journal of Virology	2015
26098315	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env.	Nat Struct Mol Biol	2015
26468324	Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.	Sci Transl Med	2015
26029368	Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques.	Immunity, inflammation and disease	2015
26023780	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.	PLoS Pathogens	2015